Clinically important interactions involving new antiepileptic drugs Yitzhak Schiller

Epilepsy is a common disease with a prevalence of about 1%, and a lifetime incidence of 2-3%.1-2

Patients with epilepsy experience recurrent unprovoked seizures. There are multiple subtypes of epileptic seizures, which vary substantially in their clinical manifestations.3,4 The common feature unifying epileptic seizures is their underlying pathophysiological basis. All epileptic seizures result from hypersynchronized increased electrical activity in cortical neurons.5